Catalent Inc (NYSE:CTLT)
Catalent, Inc. (CTLT), a global company that provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products yesterday reported their fiscal fourth quarter 2017 financial results.
Catalent reported adjusted fourth quarter earnings of $0.65 per share which beat analyst expectations of $0.57 per share and revenues of $616.9 million which beat analyst expectations of $544.4 million.
Catalent, Inc. CEO’s Comments
“We’re pleased with our performance during the fourth quarter, where we recorded double-digit organic revenue growth and segment EBITDA growth on a constant-currency basis across all three of our reporting segments,” said John Chiminski, Chairman, President and Chief Executive Officer of Catalent, Inc. “Fiscal year 2017 was strong across many fronts with financial performance above our long-term outlook, significant levels of free cash flow generation, and the completion of two strategic acquisitions, Pharmatek and Accucaps, both of which are already creating value for the company and our shareholders.” Business Wire
CTLT Technical Analysis
CTLT opened trading yesterday at $35.31 which was up from the previous day’s trading close of $35.20. CTLT closed trading yesterday at $35.36 and spiked up after market to $39.83, equivalent to a 13% increase from the closing price. Taking a look at the daily chart we can see that we are in unchartered territory as with the spike up CTLT is now trading at all time highs.
Taking a closer look at the daily chart we can see that before the spike up CTLT had already been in an overall upward trend dating back to May 4th when it traded at $28.93. CTLT has a float of 124.22 million shares and traded 1.73 times the normal daily trading volume on Monday.
For trading purposes, I would like to see CTLT open trading on Tuesday above $38.50 and if it does I would be looking to take a long position at the bell. My stop order would be $0.30 from my entry position fearing anything more than that and the stock would start to fill in the gap up.
Company Profile
Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services.
The Softgel Technologies segment provides formulation, development, and manufacturing services for softgels, which are used in a range of customer products, including prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Its principal softgel technologies include traditional softgel capsules, and Vegicaps and OptiShell capsules. The Drug Delivery Solutions segment formulates, develops, and manufactures prescription, and consumer and animal health products using proprietary technologies, including OptiMelt, OptiPact, OptiForm, and Zydis, as well as other proprietary and conventional drug delivery technologies, such as prefilled syringes; manufactures blow-fill seal unit dose, including ADVASEPT technology; develops biologic cell line, including GPEx and SMARTag technologies; and provides analytical and bioanalytical development, and testing services, as well as offers respiratory products formulation and manufacturing, micronization and particle engineering, and regulatory consulting services.
The Clinical Supply Services segment provides manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials for customer required patient kits. This segment also offers FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services.
The company serves pharmaceutical and biotechnology companies; and consumer health companies, as well as companies in other healthcare market segments, such as animal health and medical devices, and companies in industries, including cosmetics. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.